TD Cowen Lifts Natera (NTRA) Target to $240, Reiterates Buy Rating

Natera, Inc. (NASDAQ:NTRA) is one of the best gene-editing stocks to buy according to hedge funds. On November 7, Daniel Brennan, an analyst at TD Cowen, reiterated a Buy rating on Natera, Inc. (NASDAQ:NTRA) stock and lifted the price target to $240 from $215. Brennan cited a mix of factors, but key among them is Natera’s robust Q3 2025 results.

During the quarter, Natera’s sales beat estimates by 15%; management attributed the performance to “contributions from core business segments and favorable true-ups.​” The Signatera product was the most outstanding – it recorded a 78% year-over-year sales growth and achieved record quarterly volumes. Brennan described the performance as evidence of “strong market momentum”.

Independently of the analyst’s action, Natera’s management presented strategic growth initiatives and future prospects at the UBS Global Healthcare Conference 2025 on November 11. They stated that they processed approximately 893,600 tests in Q3 2025, up 15.2% year-over-year. Oncology testing volume reached 211,000 for the quarter, a 53.9% increase versus the prior year, and included a record sequential growth in clinical molecular residual disease (MRD) test units.​ Management also revealed plans to expand Medicare coverage to seven additional indications and progress with broader payer adoption.

Natera, Inc. (NASDAQ:NTRA) is a clinical genetic testing company. It specializes in non-invasive, cell-free DNA (cfDNA) technology, which allows detection and analysis of genetic material from a simple blood draw. Its main products include Panorama, a leading non-invasive prenatal test; Signatera, a personalized molecular residual disease assay for oncology; and Prospera, a cfDNA-based test for monitoring organ transplant rejection.

While we acknowledge the potential of NTRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best European Bank Stocks to Buy Now and 11 Best Solar Energy Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.